Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs BGMSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–1 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 BGMSP Matrix Metrics: DCTH 8 – 1 BGMSP

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BGMSP carries 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BGMSP currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. N/A operating margin) and revenue trajectory (+70.7% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs BGMSP
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.59β · 201% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 BGMSP)

Columns: Metric · DCTH · BGMSP
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E 133.6x N/M
PEG Ratio 1.60x N/M
EV / Revenue 6.3x N/M
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% N/A
Earnings Growth (YoY) +750.0% N/A
TTM Revenue (USD) $110M N/A
Market Cap $743.8M N/A
3. Profitability & Quality DCTH
Gross Margin 87.6% N/A
Operating Margin 5.2% N/A
Net Profit Margin 6.0% N/A
Return on Equity (ROE) 5.4% N/A
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M N/A
Cash Flow Margin 18.3% N/A
Net Cash / Leverage $53M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 109.3% (43rd %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (8) vs BGMSP (1)
Institutional Metric DCTH BGMSP Criterion Row Edge
Market Capitalization
Scale
$743.8M N/A Larger Scale DCTH
Trailing P/E Ratio
Valuation
133.6x N/M Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+70.7% N/A Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% N/A Higher Margin DCTH
Net Profit Margin
Profitability
6.0% N/A Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% N/A Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 0% ($1–$14) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.59β · 201% Vol Lower Realized Risk DCTH
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite BGMSP
Trailing 12M Revenue (USD)
Operating Scale
$110M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +54.49 pp
DCTH: -6.49% · BGMSP: -60.98%
3M Horizon DCTH +73.98 pp
DCTH: +1.57% · BGMSP: -72.41%
6M Horizon DCTH +73.98 pp
DCTH: +1.57% · BGMSP: -72.41%
1Y Horizon DCTH +73.98 pp
DCTH: +1.57% · BGMSP: -72.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCTH vs BGMSP. Trailing 12-month operating profitability (DCTH 5.2% vs BGMSP N/A) and valuation multiples (DCTH N/M vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M
BGMSP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGMSP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGMSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
BGMSP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs BGMSP Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BGMSP carries 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BGMSP currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. N/A operating margin) and revenue trajectory (+70.7% vs. N/A YoY).

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with BGMSP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, DCTH generates $110M in USD-normalized revenue versus N/A for BGMSP. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BGMSP.

DCTH screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas BGMSP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus BGMSP (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, BGMSP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 201% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.